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Background: Pulmonary arterial hypertension (PAH) is a pulmonary vascular disease with
a high mortality, characterized by typical angio-proliferative lesions. Erythropoietin (EPO)
attenuates pulmonary vascular remodeling in PAH. We postulated that EPO acts through
mobilization of endothelial progenitor cells (EPCs) and activation of the cytoprotective
enzyme heme oxygenase-1 (HO-1).
Methods: Rats with flow-associated PAH, resembling pediatric PAH, were treated with
HO-1 inducer EPO in the presence or absence of the selective HO-activity inhibitor tin-
mesoporphyrin (SnMP). HO activity, circulating EPCs and pulmonary vascular lesions
were assessed after 3weeks.
Results: In PAH rats, circulating EPCs were decreased and HO activity was increased
compared to control. EPO treatment restored circulating EPCs and improved pulmonary
vascular remodeling, as shown by a reduced wall thickness and occlusion rate of the
intra-acinar vessels. Inhibition of HO activity with SnMP aggravated PAH. Moreover, SnMP
treatment abrogated EPO-induced amelioration of pulmonary vascular remodeling, while
surprisingly further increasing circulating EPCs as compared with EPO alone.
Conclusion: In experimental PAH, EPO treatment restored the number of circulating
EPCs to control level, improved pulmonary vascular remodeling, and showed important
interplay with HO activity. Inhibition of increased HO activity in PAH rats exacerbated
progression of pulmonary vascular remodeling, despite the presence of restored number
of circulating EPCs. We suggest that both EPO-induced HO-1 and EPCs are promising
targets to ameliorate the pulmonary vasculature in PAH.
Keywords: hemodynamics, pulmonary vascular remodeling, neointimal lesions, aorto-caval shunt, pulmonary
hypertension, right ventricular hypertrophy
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Introduction
Pulmonary arterial hypertension (PAH) is a life-threatening
pulmonary vascular disease (1), affecting pediatric patients as
well as young adults (2). Despite decades of research, pediatric
patients with PAH still have a 5-year mortality rate of ~40% (2).
One of the problems is that the currently available medication
does not target the proliferative vascular lesions that are typi-
cal for PAH (3–5), i.e., neointimal and plexiform lesions. These
lesions of the small vessel walls are formed by proliferation of
endothelial and smooth muscle cells, fibrosis, thrombosis, and
inflammation (4). Although the histomorphology of PAH is well
described, the cellular mechanisms underlying this process are
still unknown (6).
There is increasing evidence that endothelial cell dysfunction
and loss of endothelial cells play a central role in the pathogene-
sis of pulmonary vascular remodeling (7–9). Hence, therapeutic
strategies should be aimed at mobilization of endothelial cells for
vascular repair (10). One of these strategies is mobilization of
bone marrow-derived endothelial progenitor cells (EPCs) (10).
Indeed in hypoxic pulmonary hypertension (PH), mobilization
of EPC appears beneficial in reducing media hypertrophy (11).
However, vascular lesions in hypoxic PH do not represent the
vessel remodeling seen in PAH (3) and the effects of EPCs on
vascular remodeling in neointimal proliferation are still unknown.
To study the pathogenesis and potential therapeutic strategies,
we use a well-characterized animal model of flow-induced PAH,
representing patients with PAH associated with congenital heart
diseases (5, 6, 12). In this model, we have recently shown that
erythropoietin (EPO) improves pulmonary vascular remodeling
through unknown mechanisms (13). EPO is a hypoxia-induced
hormone that promotes erythropoiesis. Furthermore, EPO has
been demonstrated to exert therapeutic effects in various disor-
ders affecting the vasculature, including post mechanical vascular
injury (14) and myocardial and hind-limb ischemia (15, 16).
These therapeutic effects may be mediated by the mobilization
andhoming of EPCs from the bonemarrow to the injured vascular
endothelium, leading to re-endothelialization andneovasculariza-
tion (11, 15).
Alternatively, induction of heme oxygenase-1 (HO-1) has been
implicated to play an important role in EPOs downstreammecha-
nisms (17–19). HO-1 is the inducible isoform of heme oxygenase
(HO) which catalyzes the rate-limiting step in the degradation of
heme to ferrous iron, carbon monoxide, and biliverdin. Biliverdin
is then rapidly converted to the powerful anti-oxidant bilirubin
by biliverdin reductase (20). HO-1 is expressed in response to
a variety of stresses and, in turn, its reaction products protect
against oxidative and inflammatory stress and apoptosis (21, 22).
In experimental models of hypoxia-induced PH, characterized by
isolated media hypertrophy and not the PAH-specific obliterative
pulmonary vascular remodeling, overexpression of HO-1 appears
to protect against the development of PH (23, 24).
In the present study, we postulated that the beneficial effects
of EPO on pulmonary vascular remodeling in PAH, are through
induction of HO activity and mobilization of EPCs. To test
this hypothesis, we treated rats with (flow-associated) neointimal
PAH with EPO in the presence or absence the potent selective
HO-activity inhibitor, tin-mesoporphyrin (SnMP), and measured
pulmonary vascular remodeling, hemodynamics, pulmonary HO
activity, and the number of circulating EPCs.
Materials and Methods
Animals and Study Design
Seventy-two male Wistar rats (280–300 g) were purchased from
Harlan (Zeist, The Netherlands). The experimental protocol was
approved by the institutional Animal Care and Use Committee
(University Medical Center Groningen). Animal care and experi-
ments were conducted according to the US National Institutes of
Health guidelines.
Rats were randomized into five groups: (1) flow-associated
PAH untreated (PAH, n= 17), (2) PAH treated with EPO
(PAH+EPO, n= 17), (3) PAH treated with EPO and the HO-
inhibitor SnMP (PAH+EPO+ SnMP, n= 13), (4) PAH treated
with only SnMP (PAH+ SnMP, n= 12), and (5) a control group
(CON, n= 13). Flow-associated PAH was created by subcuta-
neous injection with monocrotaline (60mg/kg, Sigma Chemical
Co., St. Louis, MO, USA) at day 0, followed by an abdominal
aorto-caval shunt at day 7, as described in detail previously (6).
EPO (40μg/kg,Darbepoetin-alpha, Aranesp®, Amgen Inc., Thou-
sand Oaks, CA, USA) was administered via a single subcutaneous
injection on the day of aorto-caval shunt surgery as described
previously (13, 16). SnMP (30μmol/kg, Sn(IV) Mesoporphyrin
IX dichloride, Frontier Scientific Inc.) was administered via two
subcutaneous injections: on the day of aorto-caval shunt surgery
and 10 days later. The control group underwent subcutaneous
saline injection followed by sham surgery. For analgesia, all rats
received buprenorphine (0.1mg/kg s.c. tid) for 2 days postopera-
tively. For measurement of hematocrit, blood (200μL) was drawn
every week starting from baseline (t= 0, day of monocrotaline
injection). For isolation of circulating EPCs, blood (1mL) was
drawn at baseline and before sacrifice (t= 28).
Of the 72 rats, all but eight successfully completed the experi-
mental protocol. In four of these eight rats, shunt surgery was not
successful: two rats died due to acute surgery-related complica-
tions (PAH n= 1, PAH+ SnMP, n= 1), one underwent early elec-
tive sacrifice because of postoperative paresis of hind legs (PAH)
and in one rat there was no shunt present at sacrifice (PAH). Of
the other four rats, one underwent early elective sacrifice because
of extensive unexplained wounds to the snout (CON), one died
prematurely due to unknown causes (PAH+EPO) and two rats
died during orbital function for blood withdrawal (PAH+EPO,
n= 1; PAH+ SnMP, n= 1). All these eight rats were excluded
from analysis.
Circulating Endothelial Progenitor Cells
For measuring the levels of circulating EPCs, we used a cell
culturing and staining technique that has been described previ-
ously (16, 25), since fluorescence activated cell sorting (FACS) is
impossible for identifying rat EPCs due to the lack of rat-specific
EPC antigens.
Mononuclear cells were isolated from 1mL of peripheral blood
by density gradient centrifugation with Histopaque-1083, accord-
ing to manufacturer’s instructions (Sigma Chemical, St. Louis,
MO, USA). Isolated mononuclear cells were seeded in triplicate
on 1% gelatine-coated 96-well plates (BD BioCoat, Bedford, MA,
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USA), in endothelial cell basal medium (Cambrex Bioproducts,
Clonetics, NJ, USA) supplemented with 2% fetal bovine serum,
EGM-2 SingleQuots (Clonetics), Penicillin (100U/mL), and
Streptomycin (100μg/mL). After 2 days of culture, the adherent
cells were carefully washed with medium and co-stained with DiI
AcLDL (1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine-
labeled acetylated Low-Density Lipoprotein, 10μg/mL;Molecular
Probes, Invitrogen, Carlsbad, CA, USA) and FITC-conjugated
BS lectin 1 (fluorescein isothyiocyanate-labeled Bandeiraea
Simplicifolia lectin 1, 10μg/mL; Sigma-Aldrich, Zwijndrecht,
Netherlands). DAPI (40,6-diamidino-2-phenyindole, dilactate,
Sigma-Aldrich, Zwijndrecht, Netherlands) was used for nuclear
staining. Images were captured using an LSM 410 fluorescence
microscope with a magnification of 100 (Carl Zeiss, Jena, Ger-
many). Double positive cells for DiI AcLDL and lectin staining
were considered an EPC and counted by co-localization analy-
sis using Image-Pro Plus for Windows software (version 4.5) by
an investigator blinded to treatment. DAPI staining served as a
control to see whether the double positive cells were cells with a
nucleus. For every blood sample, the average number of EPCs was
calculated from six high-power field images, two from each well.
Hemodynamic Measurements
Three weeks after aorto-caval shunt surgery (t= 28), we anes-
thetized the animals and measured hemodynamics as described
previously. Briefly, pulmonary and systemic arterial pressures
were measured using fluid-filled catheters and right ventricular
contractility was measured using a 2-French Microtip pressure
transducer (Millar Instr. Inc., Houston, TX, USA). After comple-
tion of hemodynamic measurements, blood samples were drawn
from the left carotid artery, distal, and proximal inferior caval vein
(below and, respectively, above the level of the aorto-caval shunt)
in order to determine oxygen saturation and confirm the presence
of a shunt by significant oxygen step-up (31 10%).
Pulmonary Vascular Remodeling
Pulmonary morphometric analysis was assessed as described pre-
viously (5, 6, 9). Briefly, the right lung was frozen in liquid
nitrogen for molecular analyses. The left lung was fixated by
filling the airways with 3.6% formalin at a pressure of 20 cmH2O.
Deparaffinized pulmonary 5μm thick sections were stained with
hematoxylin–eosin and Verhoef elastin-stain for morphometric
analysis of vascular dimensions. In the lung sections, all transver-
sally cut arteries with a diameter 50μm (pre-acinar arteries)
and 40 randomly chosen vessels (10 in each left lung quadrant)
with a diameter<50μm (intra-acinar vessels) were quantitatively
analyzed at 200 and 400magnification using image analysis soft-
ware (Image-Pro Plus forWindows, version 4.5). In the pre-acinar
arteries, wall thickness and medial wall/lumen ratio were mea-
sured and calculated. In the intra-acinar pulmonary vessels, wall
thickness wasmeasured in addition to occlusion scores, calculated
according to the following formula: (outer vessel area  luminal
area)/(outer vessel area). Muscularization of 40 small pulmonary
vessels was assessed as described previously (6, 12).
Heme Oxygenase Activity Measurement
To determine pulmonary HO activity at day 28, we performed an
HO-activity assay by measurement of bilirubin (and biliverdin)
generation using HPLC techniques, slightly modified from
previously described (26). In short, proteins were isolated from
frozen lung by pulverization using a Mikro-dismembrator (Sar-
torius B. Braun Biotech Int., Melsungen, Germany, 2000 rpm for
40 s). Lung homogenate was resuspended (40mg/mL) in lysis
buffer (20mM Tris/250mM sucrose, pH= 8.5; supplemented
with protease inhibitors) and subsequently lysed by three freeze-
thaw cycles. Next, the lysate was centrifuged at 13,000 rpm at 4°C
for 10min. The supernatant was used for the HO-activity assay
and the measured protein concentration was used for normal-
ization. Samples for measurement on an HPLC (Spectra-Physics
Analytical, Spectrasystem SCM400) equipped with a 5μm Dis-
covery C18 column and a Discovery C18 Supelguard Cartridge
5μm particle size precolumn (both Sigma-Aldrich) were sup-
plemented with vitamin C to prevent oxidation of bilirubin or
biliverdin. As controls for HO activity, we used untreated fibrob-
lasts in combination with fibroblasts treated for 24 h with 10μM
curcumin (26).
Quantitative Real-Time-PCR
Real-time PCR (RT-PCR) was performed using standard assays.
Total RNA was isolated from pulmonary tissue using TRIzol
reagent (Invitrogen). RT-PCR experiments were performed on a
CXF384 real-time system C1000 Thermal cycler (BioRad Labo-
ratories, Veenendaal, The Netherlands). cDNA was synthesized
using Moloney murine leukemia virus reverse transcriptase and
random primers (Invitrogen, Burlington, ON, Canada). RT-PCR
was conducted using SYBR Green PCR Master Mix according
to the manufacturer’s instructions (Eurogentec, San Diego, CA,
USA). Primer sequences are available on request. Expression levels
were obtained from a dilution standard curve and compared with
those of 36B4 RNA in order to calculate the relative expression
levels.
Statistical Analysis
Data are presented asmean SEMormedian (range). Differences
between the PAH and CON groups were analyzed using t-tests for
normally distributed data and Mann–Whitney U testing for not
normally distributed data. Differences between the untreated and
treated PAH groups (groups 1–4) were tested by one-way ANOVA
followed by Fisher’s protected LSD post hoc testing (hematocrit,
hemodynamics, RVhypertrophy, and pulmonary vascular remod-
eling) and Kruskall–Wallis followed by Mann–Whitney post hoc
testing with Bonferroni correction (number of EPCs) was used.
Alpha was chosen to be 0.05. A two-tailed p-value <0.05 was
considered statistically significant. SPSS 16.0 was used to perform
the analyses.
Results
Flow-Associated PAH Rat Model
Flow-associated PAH was confirmed by histology, pathology,
and hemodynamics as described previously (5, 6). Briefly, PAH
rats showed advanced pulmonary vascular remodeling, includ-
ing significantly increased wall thickness, occlusion scores and
muscularization of intra-acinar vessels as well as increased wall
thickness and wall/lumen ratio of pre-acinar pulmonary vessels
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FIGURE 1 | Flow-associated PAH and effects of EPO treatment.
Flow-associated PAH and effects of EPO treatment on (A) wall thickness of
intra-acinar pulmonary vessels, (B) right ventricular hypertrophy
[RV/(LV+ IVS)], and (C) systolic pulmonary arterial pressure. (D) Examples of
pulmonary histopathology (Verhoeff-staining) of intra-acinar pulmonary
vessels. CON, control group, n= 12; PAH, untreated pulmonary arterial
hypertension, n= 12–14; PAH+EPO, PAH treated with erythropoietin
(EPO), n= 12–15. Differences between the PAH and CON groups were
analyzed using t-tests for normally distributed data and Mann–Whitney U
testing for not normally distributed data. Differences between the untreated
and treated PAH groups (groups 1–4) were tested by one-way ANOVA
followed by Fisher’s protected LSD post hoc testing (hematocrit,
hemodynamics, RV hypertrophy, pulmonary vascular remodeling). *p<0.05
vs. CON, #p<0.05 vs. PAH.
as compared to control (Figures 1A,D; Table 1). PAH rats had
significantly increased right ventricular hypertrophy, increased
right atrial and pulmonary arterial pressures, and decreased right
ventricular contractility (Figures 1B,C; Table 1).
Increased HO Activity and Decreased Number of
Circulating EPCs in PAH
At day 28, rats with PAH had increased pulmonary HO activity
and HO-1 mRNA levels (Figures 2A,B). The number of circulat-
ing EPCs tended to be lower in PAH, although not reaching statis-
tical significance (p= 0.1, Figure 2C). There were no differences
in baseline EPC number or hematocrit (data not shown).
Effects of EPO in PAH
EPO treatment improved pulmonary vascular remodeling, as
previously shown by reduced wall thickness and occlusion
scores of intra-acinar pulmonary vessels, compared with PAH
(Figures 1A,D; Table 1). Hemodynamics remained unchanged,
which is consistent with previous experiments (13). EPO
treatment did not further increase pulmonary HO activity
at day 28 (Figure 2A), whereas HO-1 mRNA expression
levels were further increased (Figure 2B). EPO treatment
increased the number of circulating EPCs to levels similar
to CON (Figure 2C). Hematocrit levels increased significantly
after EPO treatment (Figure 3A) demonstrating the successful
administration of EPO. Taken together, EPO improved pul-
monary vascular remodeling and increased the number of
circulating EPCs.
Effects of Inhibition of HO Activity in PAH
SnMP successfully inhibited HO activity in both PAH+ SnMP
and PAH+EPO+ SnMP to levels as measured in CON
(Figure 3B), whereas SnMP did not decrease HO-1 mRNA levels
(Figure 3C), which confirms its function in inhibitingHO activity
and not HO-1 transcription. SnMP treatment in the absence of
EPO treatment aggravated pulmonary vascular remodeling to
levels worse than seen in untreated PAH: significantly increased
wall thickness and occlusion scores of intra-acinar pulmonary
vessels and increased wall-lumen ratio of pre-acinar pulmonary
arteries (Figure 3B; Table 1). Interestingly, SnMP treatment
alone tended to increase circulating EPCs (PAH+ SnMP vs.
PAH p= 0.09) to a level comparable to that after EPO treatment
(PAH+EPO; Figure 3B). Taken together, inhibition of HO
activity worsened pulmonary vascular remodeling, despite
increasing the number of circulating EPCs.
Effects of EPO and Inhibition of
HO Activity in PAH
EPO-mediated amelioration of pulmonary vascular remodeling
was abrogated following co-treatment with SnMP, while further
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TABLE 1 | Animal characteristics.
CON PAH PAH+ EPO PAH+ EPO+ SnMP PAH+ SnMP
Hemodynamics
Mean pulmonary artery pressure 20 1 32 1* 35 1 37 3 34 2
Systolic pulmonary arterial pressure (mmHg) 30 1 54 3* 56 3 56 4 56 6
Mean systemic arterial pressure (mmHg) 89 2 63 4* 71 6 71 5 67 4
dP/dT indexed max 106 8 71 2* 76 6 74 7 67 6
 dP/dT indexed max 91 7 55 16* 80 6 56 18 62 7
Heart rate (beats per minute) 343 20 310 14 321 15 312 18 328 13
Pathology
Body weight at sacrifice (g) 390 8 350 8* 346 5 343 5 343 5
RV hypertrophy, RV/(LV+ IVS) 0.25 0.01 0.47 0.03* 0.47 0.03 0.47 0.03 0.42 0.04
RV weight (mg) 0.21 0.02 0.44 0.02 0.44 0.03 0.40 0.03 0.38 0.03
Pulmonary vascular morphometry
Intra-acinar pulmonary vessels<50μm
Totally muscularized 2.6 1.2 20.3 3.5* 18.9 2.6 24.0 5.6 28.8 6.1
Partly muscularized 2.7 0.9 9.4 2.5* 9.6 2.0 17.6 2.6 13.1 3.0
Pre-acinar pulmonary vessels>50μm
Wall thickness (μm) 7.3 1.3 15.6 1.5* 16.1 1.8 15.4 1.9 16.6 3.1
Wall/lumen ratio 0.08 0.01 0.15 0.01* 0.14 0.01 0.15 0.02 0.24 0.05§,#
Data are presented as meanSEM. CON, control group, n=12; PAH, untreated pulmonary arterial hypertension, n=14; PAH+EPO, PAH treated with erythropoietin (EPO), n=15;
PAH+EPO+SnMP, PAH treated with EPO and tin-mesoporphyrin (SnMP), n=13; PAH+SnMP, PAH treated with SnMP, n=10; RV, right ventricle; ( )dP/dT indexed max, RV
contractility, maximal rate of increase or decrease in RV pressure [calculated as the variation in pressure (P) with time (T) corrected for RV systolic pressure]; LV, left ventricle; IVS,
interventricular septum. Differences between the PAH and CON groups were analyzed using t-tests for normally distributed data and Mann–Whitney U testing for not normally distributed
data. Differences between the untreated and treated PAH groups (groups 1–4) were tested by one-way ANOVA followed by Fisher’s protected LSD post hoc testing (hematocrit,
hemodynamics, RV hypertrophy, pulmonary vascular remodeling).
*p<0.05 vs. CON.
#p< 0.05 vs. PAH.
§p< 0.05 vs. PAH+EPO+SnMP.
increasing the number of circulating EPCs compared to EPO
treatment alone (Figure 3B). EPO-induced HO-1 mRNA lev-
els remained high in the presence of the HO-activity inhibitor
SnMP (Figure 3C). Taken together, inhibition of HO activity
strongly attenuated the protective effects of EPO on pulmonary
vascular remodeling despite further increasing the number of
circulating EPCs.
Effects of EPO and Inhibition of HO Activity on
EPC Homing Factors and Markers of
Inflammation
In order to investigate the effects of EPO on factors involved
in the homing of circulating EPCs to the diseased vessel
endothelium, we studied two stimuli required for EPCs to
home to diseased vascular walls: vascular endothelial growth
factor (VEGF) and its two receptor subtypes (VEGF-R1,
VEGF-R2) and stromal derived growth factor-1 (SDF-1)
(16, 27). Since inflammatory processes are involved in the
pathophysiology of PAH and since HO activity has potent
anti-inflammatory properties (28), we also measured monocyte
chemo attractant protein-1 (MCP-1) levels, a major inflammatory
marker, in order to study the effects of modulation of HO
activity using EPO and SnMP on inflammatory processes
in PAH.
Pulmonary VEGF-R2 mRNA expression levels were decreased
and SDF-1 levels were increased in PAH. After EPO treatment,
these mRNA levels were unchanged (Figure 3C). Interestingly,
EPO treatment together with SnMP tended to increase mRNA
expression levels of VEGF-R2 and SDF-1, whereas SnMP alone
did not alter these mRNA levels. Regarding inflammation,MCP-1
mRNA expression levels were significantly increased in PAH rats,
compared to CON (Figure 3C). EPO treatment with or with-
out SnMP did not influence these levels. Taken together, EPO
and SnMP did not influence EPC homing factors or markers of
inflammation.
Discussion
EPO treatment has been demonstrated to have beneficial effects
on pulmonary vascular remodeling in PH. This study describes
the interplay between EPO treatment, circulating EPCs and
HO activity in a rat model of experimental flow-associated
PAH. This model is characterized by a neointimal-type of pul-
monary vascular remodeling, a decreased number of circulat-
ing EPCs, while both gene expression and activity of HO-1
are increased; Treatment with EPO restored the number of
circulating EPCs and was associated with improved vascu-
lar remodeling. Twenty-one days after EPO administration, no
change in HO activity could be demonstrated, although HO-
1 gene expression was further increased. In contrast, reducing
HO-1 activity to control level using tin-mesoporphyrin seri-
ously aggrevated pulmonary vascular remodeling, despite an
associated increase in circulating EPCs. The combination of
EPO treatment and simultaneously reduced of HO activity (to
control level) resulted in a cumulative increase in circulating
EPCs, however without any improvement of pulmonary vascular
remodeling.
What do we learn from these observations regarding the mech-
anisms by which EPO treatment exerts its ameliorating effects on
pulmonary vascular remodeling in PAH?
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FIGURE 2 | Effect of EPO treatment on HO activity and EPCs. (A) Heme
oxygenase activity measured in whole lung lysates (methods). (B) Heme
oxygenase mRNA expression, relative to 36B4 expression in whole lung.
(C) Number of Endothelial Progenitor Cells (EPC) in blood at the day of sacrifice.
(D) Example of fluorescence microscope picture of EPCs in blood. CON, control
group, n= 4–8; PAH, untreated pulmonary arterial hypertension, n= 8–12;
PAH+EPO, PAH treated with erythropoietin (EPO), n= 5–8. Differences
between the PAH and CON groups were analyzed using t-tests for normally
distributed data and Mann–Whitney U testing for not normally distributed data.
Differences between the untreated and treated PAH groups (groups 1–4) were
tested by one-way ANOVA followed by Fisher’s protected LSD post hoc testing
(hematocrit, hemodynamics, RV hypertrophy, pulmonary vascular remodeling)
and Kruskall–Wallis followed by Mann–Whitney post hoc testing with Bonferroni
correction (number of EPCs) was used. *p<0.05 vs. CON, #p<0.05 vs. PAH.
Endothelial Progenitor Cells
Consistent with previous experimental data and with recent
reports in human PAH, both idiopathic and associated with
congenital heart disease, we observed decreased number of cir-
culating EPCs in untreated PAH (13, 29, 30). This shortage
of circulating EPCs in PAH may contribute to the progression
of pulmonary endothelial dysfunction and pulmonary vascular
remodeling, since EPCs are believed to be able to incorporate
into damaged endothelium and potentially repair this endothe-
lium. Bone marrow-derived EPCs have been observed in dis-
eased pulmonary vessel walls of experimental models of untreated
hypoxia and monocrotaline-induced PH (31, 32) and the incor-
poration of EPCs into this diseased pulmonary endothelium has
been suggested to improve pulmonary vascular remodeling (11).
Until now, such improvements have been observed only after
administration of genetically modified and functionally enhanced
EPCs inmodels ofmedia hypertrophy type of pulmonary vascular
remodeling (33, 34).
The role of bone marrow-derived progenitor cells and their
tissue-restoring potential in PAH remain largely unknown and
whether the beneficial effect of EPO treatment in PAH is through
this mechanism remains to be demonstrated. In the current
study, reducing HO activity by SnMP in experimental PAH,
induced an increase in circulating EPCs, but was associated with
a further deterioration of pulmonary vascular remodeling. This
observation implies that HO activity is crucially important in
PAH, either for circulating EPCs to exert their healing effect on
the pulmonary vasculature, or because of an EPC-independent
vascular protective HO-effect, for which the increase in EPCs
could not compensate. In both explanations,HO-1 appears crucial
for a vascular protective effect in PAH.
Available evidence supporting the first concept that HO-1
activity is essential for EPCs to function normally and to exert
the beneficial effect of EPO in PAH includes previous findings
that (1) the function of EPCs and its homing to the damaged
pulmonary vasculature is hampered in humanswith PAH (29, 30);
(2) inhibition of HO activity leads to dysfunctional EPCs (35); (3)
HO activity promotes EPCs to home (36, 37); (4) beneficial effects
of EPO fade out in the presence of HO-activity inhibitors in WT
mice and are absent HO-1 knock out mice (17, 19); and (5) HO-
1/carbon monoxide enhances re-endothelialization after vascular
injury via promoting mobilization of circulating EPCs (38).
Heme Oxygenase Activity
It is currently well established that HO-1 expression provides
a general cyto- and tissue-protective effect, as a generalized
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FIGURE 3 | (A) Hematocrit levels throughout the study time points at
x-axis in days. Data are meanSEM. CON, control group, n= 10; PAH,
untreated pulmonary arterial hypertension, n= 12; PAH+EPO, PAH
treated with erythropoietin (EPO), n= 14. *p<0.05 vs. CON, #p<0.05 vs.
PAH PAH+EPO+SnMP, PAH treated with EPO and tin-mesoporphyrin
(SnMP), n= 12; PAH+SnMP, PAH treated with SnMP, n= 9. (B) Effects
of HO activity blockade on HO activity, number of circulating EPCs and
pulmonary vascular remodeling. CON, control group, n= 4–12; PAH,
untreated pulmonary arterial hypertension, n= 8–14; PAH+EPO, PAH
treated with erythropoietin (EPO), n= 5–15. PAH+EPO+SnMP, PAH
treated with EPO and tin-mesoporphyrin (SnMP), n= 5–13; PAH+SnMP,
PAH treated with SnMP, n= 6–10. (C) Effects of HO activity blockade
gene expression. CON, control group, n= 5; PAH, untreated pulmonary
arterial hypertension, n= 6; PAH+EPO, PAH treated with erythropoietin
(EPO), n= 6. PAH+EPO+SnMP, PAH treated with EPO and
tin-mesoporphyrin (SnMP), n= 6; PAH+SnMP, PAH treated with SnMP,
n= 6.VEGF-R2, vascular endothelial growth factor receptor 2; SDF-1,
stromal derived growth factor-1; MCP-1, monocyte chemoattractant
protein-1. mRNA expression levels relative to 36B4 mRNA levels.
Differences between the PAH and CON groups were analyzed using t-tests
for normally distributed data and Mann–Whitney U testing for not normally
distributed data. Differences between the untreated and treated PAH
groups (groups 1–4) were tested by one-way ANOVA followed by Fisher’s
protected LSD post hoc testing (hematocrit, hemodynamics, RV
hypertrophy, and pulmonary vascular remodeling) and Kruskall–Wallis
followed by Mann–Whitney post hoc testing with Bonferroni correction
(number of EPCs) was used. #p<0.05 vs. PAH, †p<0.05 vs.
PAH+EPO, §p<0.05 vs. PAH+SnMP.
protective response to environmental stressors, including vas-
cular shear stress. These protective effects of HO-1 are con-
tributed to its properties to inhibit or modulate inflammatory,
apoptotic and proliferative processes. HO-1 plays an essential
role in such processes, via the production of the gasotransmit-
ter carbon monoxide, the anti-oxidant bilirubin, and of iron,
that co-induces the iron scavenger ferritin (21, 22). Inflamma-
tory, apoptotic, and proliferative processes have been demon-
strated to contribute to the progression of PAH (12, 28) and
experimental induction of HO-1, either chemically or using
transgenic mice with lung-specific HO-1-overexpression, inhib-
ited the development of PAH in animal models (23, 24). In
the present study, HO-1 mRNA and HO-1 activity levels were
augmented in untreated PAH and inhibition of HO activity wors-
ened pulmonary vascular remodeling in the presence of normal
level of circulating EPCs. This observation supports the con-
cept that increased HO activity reflects an intrinsic protective
response to increased inflammatory stress in PAH (39). Indeed,
in untreated PAH rats, we found signs of increased inflammation
involving highly increased levels of MCP-1, a monocyte chemo
attractant and marker for inflammation, analogous to studies in
humans with PAH (40). The importance of HO-1 induction in
the pulmonary vascular bed is further emphasized by the recent
finding that overexpression of HO-1 improves the beneficial
effects of mesenchymal stromal cells in hypoxic PH (41). Puta-
tively, HO-1 activation by specific microRNAs may initiate the
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anti-inflammatory effects, as has been suggested by recent studies
in ECs (42).
EPO is known to induce HO activity both in physiological and
diseased states.While EPO treatment resulted in a further increase
of HO-1 mRNA levels in concordance with previous findings in
experimental models of kidney failure and myocardial infarction
(17, 19), HO-1 activity, a more specific assessment for functional
properties, was not further enhanced. The latter, however, may be
explained by the timing of the experiments: EPO-mediated HO-
1 induction is likely highest within the first week. After 2weeks,
most of the induced HO-1 activity may have faded. Consequently,
the presented HO-activity data may be an underestimation of
the initial HO-1 induction by EPO. Interestingly, other potent
activators of HO-1, such as the anti-oxidant Protandim, are also
successful in increasing the protective response in PAH (43).
Enhancement of HO-1 may not only target the pulmonary vas-
cular bed but also the right ventricle, which affects outcome in
PAH. Protandim has been shown to target RV fibrosis (44), which
is an important feature in RV dysfunction in response to increased
afterload (45–48).
Recently, several studies have suggested that HO-1 and its
byproduct CO also may induce cytoprotective properties by other
mechanisms, then attenuating apoptosis and inflammation. HO-1
potentially impacts the regulation of autophagy, a vital cellular
process, which may in part contribute to an independent cytopro-
tective effect of HO-1 (49).
The results of the current study show that both EPO and
HO-1 have beneficial effects on pulmonary vascular remod-
eling in experimental PAH and both interact with circulating
endothelial cells. The results further indicate that all three, EPO,
EPCs, and HO-1, are potential therapeutic targets to improve
pulmonary vascular remodeling in PAH. Whether intrinsic func-
tioning and/or homing of these circulating EPCs in the pulmonary
vasculature is affected by EPO or HO-1 or both cannot be con-
cluded from the current data. Our finding that inhibition of HO
activity by SnMP boosted the mobilization of EPCs is intriguing,
and could be related to feedbackmechanisms that sense the lack of
functional EPCs homing to the vasculature or sense the need for
clinical improvement. Future experiments to address this question
may use chimeric PAH rats, lethally radiated and transplanted
with green fluorescent or otherwise marked bone marrow cells, to
study themigration and homing of bonemarrow-derived EPCs in
the pulmonary endothelium and its effects on pulmonary vascular
remodeling.
Since HO activity appears to be necessary for EPC-mediated
repair, this suggests that EPC therapy for PAH patients could be
coupled to HO-1 induction using, e.g., EPO. This is further sup-
ported by recent evidence that EPC therapy is more efficient when
HIF-1alpha, an inductor of HO-1-expression, is activated (50).
Several limitations should be addressed as they may have influ-
enced the outcome of the study. At first, the design of the present
study did not allow us to analyze the incorporation of EPCs within
the pulmonary vascular bed, and it is therefore not possible to
assess the fate of the increased number of circulating EPCs after
EPO and/or HO-inhibition. The isolated mononuclear cells in
our study likely contain a mixture of progenitor cells in different
developing stages; nevertheless, the majority of them are expected
to be EPCs. In this study, we did not use a control group treated
with SnMP alone since tissue HO-1 expression is generally low
in the absence of stress and SnMP is not causing harm under
these conditions. In fact, it has been given as drug to prevent
baby jaundice: the uses of synthetic heme analogs (SnMP) that
are competitive inhibitors of heme oxygenase, the rate-limiting
enzyme in the production of bilirubin, represent a novel means of
controlling severe hyperbilirubinemia in the newborn (51). This,
and the observation that in the current experiment, SnMP reduced
HO-1 activity to levels not lower than controls, makes clear that
theoretical HO-1-depletion effects are not to be expected. Also,
we used SnMP, which inhibits the activity of both HO-1 and HO-
2 isoforms. Hence it is possible that some of the potent effects of
SnMP could be attributed in part to inhibition of HO-2 activity.
However, HO-2 is the constitutive isoform, whereas HO-1 is the
inducible isoform. From the measured mRNA expression levels,
one might have concluded that HO-1 was activated upon EPO
treatment, but, as mentioned above, in this study wemeasured the
actual HO activity only after 3weeks, which is likely an underesti-
mation of the HO activity shortly following EPO treatment. Fur-
thermore, the effect of multiple doses of EPO was not addressed
in the present study.
In conclusion, in this in vivomodel of flow-associated PAH we
showed that EPO treatment restored the number of circulating
EPCs to control level, improved pulmonary vascular remodeling,
and showed important interplay with HO activity. Inhibition of
increased HO activity in PAH rats exacerbated progression of
pulmonary vascular remodeling, despite the presence of restored
number of circulating EPCs. Moreover, EPO-induced ameliora-
tion of disease was abrogated when HO activity was reduced.
These findings suggest that EPO-mediated HO-1 and EPCs both
provide potential therapeutic targets in this still devastating pul-
monary vascular disease.
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